JP2004507231A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004507231A5 JP2004507231A5 JP2002510097A JP2002510097A JP2004507231A5 JP 2004507231 A5 JP2004507231 A5 JP 2004507231A5 JP 2002510097 A JP2002510097 A JP 2002510097A JP 2002510097 A JP2002510097 A JP 2002510097A JP 2004507231 A5 JP2004507231 A5 JP 2004507231A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antigen
- composition according
- encoding
- immunological epitope
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 description 15
- 239000000427 antigen Substances 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- 230000001900 immune effect Effects 0.000 description 10
- 230000000139 costimulatory effect Effects 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 108010084313 CD58 Antigens Proteins 0.000 description 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical group NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- 108010082808 4-1BB Ligand Proteins 0.000 description 1
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100022002 CD59 glycoprotein Human genes 0.000 description 1
- 102100025221 CD70 antigen Human genes 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108700037122 EWS-FLI fusion Proteins 0.000 description 1
- 101710147220 Ent-copalyl diphosphate synthase, chloroplastic Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 101100011800 Escherichia coli (strain K12) epmA gene Proteins 0.000 description 1
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 description 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000764263 Homo sapiens Tumor necrosis factor ligand superfamily member 4 Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 1
- 101710093778 L-dopachrome tautomerase Proteins 0.000 description 1
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- 108010008707 Mucin-1 Proteins 0.000 description 1
- 102100023123 Mucin-16 Human genes 0.000 description 1
- 102100034263 Mucin-2 Human genes 0.000 description 1
- 108010008705 Mucin-2 Proteins 0.000 description 1
- 101100391191 Mus musculus Foxo1 gene Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 102100021768 Phosphoserine aminotransferase Human genes 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 description 1
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 description 1
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 1
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 description 1
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 101100518993 Xenopus laevis pax3-a gene Chemical group 0.000 description 1
- 101100518994 Xenopus laevis pax3-b gene Chemical group 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 208000024389 cytopenia Diseases 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 101150002399 poxA gene Proteins 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 108700042226 ras Genes Proteins 0.000 description 1
- 101150047061 tag-72 gene Proteins 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21171700P | 2000-06-15 | 2000-06-15 | |
| PCT/US2001/019201 WO2001095919A2 (en) | 2000-06-15 | 2001-06-15 | A recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004507231A JP2004507231A (ja) | 2004-03-11 |
| JP2004507231A5 true JP2004507231A5 (enExample) | 2008-07-31 |
Family
ID=22788060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002510097A Pending JP2004507231A (ja) | 2000-06-15 | 2001-06-15 | 免疫応答を向上させるための、ｇｍ−ｃｓｆを発現する組換え非−複製性ウィルスおよびその使用 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1292694A2 (enExample) |
| JP (1) | JP2004507231A (enExample) |
| AU (2) | AU2001268452B2 (enExample) |
| CA (1) | CA2412050C (enExample) |
| WO (1) | WO2001095919A2 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ755300A0 (en) | 2000-05-17 | 2000-06-08 | Monash University | Immune potentiating compositions |
| US7628980B2 (en) | 2000-11-23 | 2009-12-08 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
| US6684646B2 (en) | 2001-05-22 | 2004-02-03 | Integrated Biosystems, Inc. | Systems and methods for freezing, storing and thawing biopharmaceutical material |
| JP4801880B2 (ja) | 2002-04-19 | 2011-10-26 | バヴァリアン・ノルディック・アクティーゼルスカブ | 新生仔予防接種用変異ワクシニアウイルスアンカラ |
| AU2003900767A0 (en) * | 2003-02-21 | 2003-03-13 | St Vincent's Hospital Sydney Limited | Idiotypic vaccine |
| BRPI0413334A (pt) * | 2003-09-05 | 2006-10-10 | Sanofi Pasteur Ltd | vetores de multiantìgenos para melanoma |
| EP1687022A4 (en) | 2003-11-12 | 2008-02-13 | Medical Res Council | RENTA: HIV IMMUNOGEN, AND USES OF RENTA |
| EA010374B1 (ru) * | 2004-07-16 | 2008-08-29 | Микромет Аг | Полипептиды с повышенной экспрессией |
| AU2007256717B2 (en) | 2006-06-02 | 2013-06-20 | International Aids Vaccine Initiative | HIV-1 Clade A consensus sequences, antigens, and transgenes |
| WO2010020056A1 (en) * | 2008-08-21 | 2010-02-25 | Ottawa Hospital Research Institute | Engineered synergistic oncolytic viral symbiosis |
| CA2742049A1 (en) * | 2008-10-31 | 2010-05-06 | The Brigham And Women's Hospital, Inc. | Vaccination with poxvirus vectors via mechanical epidermal disruption |
| US8691502B2 (en) | 2008-10-31 | 2014-04-08 | Tremrx, Inc. | T-cell vaccination with viral vectors via mechanical epidermal disruption |
| KR102007444B1 (ko) | 2011-04-25 | 2019-08-06 | 어드밴스드 바이오사이언스 라보라토리즈, 인코포레이티드 | 절단형 hiv 피막 단백질(env), 이와 관련된 방법 및 조성물 |
| PT2691530T (pt) | 2011-06-10 | 2018-05-10 | Univ Oregon Health & Science | Glicoproteínas e vectores recombinantes cmv |
| EP2586461A1 (en) | 2011-10-27 | 2013-05-01 | Christopher L. Parks | Viral particles derived from an enveloped virus |
| WO2013093629A2 (en) | 2011-12-20 | 2013-06-27 | Netherlands Cancer Institute | Modular vaccines, methods and compositions related thereto |
| US9347065B2 (en) | 2012-03-29 | 2016-05-24 | International Aids Vaccine Initiative | Methods to improve vector expression and genetic stability |
| ES2631608T3 (es) | 2012-06-27 | 2017-09-01 | International Aids Vaccine Initiative | Variante de la glicoproteína Env del VIH-1 |
| WO2014040025A2 (en) | 2012-09-10 | 2014-03-13 | International Aids Vaccine Initiative | Immunogens of hiv-1 broadly neutralizing antibodies, methods of generation and uses thereof |
| US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
| EP2873423B1 (en) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
| CN105744950A (zh) * | 2013-11-05 | 2016-07-06 | 巴法里安诺迪克有限公司 | 用于使用表达肿瘤抗原的痘病毒和免疫检查点抑制剂的拮抗剂和/或激动剂治疗癌症的组合疗法 |
| WO2015171975A1 (en) | 2014-05-09 | 2015-11-12 | The Regents Of The University Of Michigan | Use of modified banana lectin in purification of glycoproteins |
| US10093720B2 (en) | 2014-06-11 | 2018-10-09 | International Aids Vaccine Initiative | Broadly neutralizing antibody and uses thereof |
| JP5917626B2 (ja) * | 2014-07-28 | 2016-05-18 | トレムアールエックス， インコーポレイテッド | 機械的表皮破壊を介したポックスウイルスベクターによるワクチン接種 |
| US9931394B2 (en) | 2015-03-23 | 2018-04-03 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
| US9925258B2 (en) | 2015-10-02 | 2018-03-27 | International Aids Vaccine Initiative | Replication-competent VSV-HIV Env vaccines |
| TWI733719B (zh) | 2015-12-07 | 2021-07-21 | 美商河谷控股Ｉｐ有限責任公司 | 改善的組合物及用於新表位之病毒遞送的方法及其應用 |
| CN108567977B (zh) * | 2017-03-13 | 2022-04-12 | 复旦大学 | 一种免疫增强剂、免疫治疗药物组合物及其制备与用途 |
| JP2022512593A (ja) * | 2018-10-04 | 2022-02-07 | スクイーズ バイオテクノロジーズ カンパニー | 抗原提示細胞の機能を増強するための生体分子の細胞内送達 |
| TW202146427A (zh) | 2020-02-21 | 2021-12-16 | 美商國際愛滋病疫苗開發股份有限公司 | 用於預防冠狀病毒疾病的疫苗組合物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5833975A (en) * | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
| EP0789774A2 (en) * | 1994-10-03 | 1997-08-20 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system |
| AU4448597A (en) * | 1996-10-04 | 1998-05-05 | Connaught Laboratories Limited | Treatment of cancer using a recombinant poxvirus containing nucleic acid sequence encoding a cytokine |
-
2001
- 2001-06-15 AU AU2001268452A patent/AU2001268452B2/en not_active Expired
- 2001-06-15 CA CA2412050A patent/CA2412050C/en not_active Expired - Lifetime
- 2001-06-15 JP JP2002510097A patent/JP2004507231A/ja active Pending
- 2001-06-15 AU AU6845201A patent/AU6845201A/xx active Pending
- 2001-06-15 EP EP01946395A patent/EP1292694A2/en not_active Ceased
- 2001-06-15 WO PCT/US2001/019201 patent/WO2001095919A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004507231A5 (enExample) | ||
| EP2809788B1 (en) | Adenoviruses expressing heterologous tumor-associated antigens | |
| Surman et al. | Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen | |
| CA2354024A1 (en) | A recombinant vector expressing multiple costimulatory molecules and uses thereof | |
| Irvine et al. | Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors | |
| US6855320B2 (en) | Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity | |
| EP3095798B1 (en) | Immunity enhancing therapeutic vaccine for hpv and related diseases | |
| CA2412050A1 (en) | A recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses | |
| CA2293692A1 (en) | Methods and reagents for vaccination which generate a cd8 t cell immune response | |
| Qazi et al. | Enhancement of DNA vaccine potency by linkage of Plasmodium falciparum malarial antigen gene fused with a fragment of HSP70 gene | |
| AU2019361280B2 (en) | Teleost invariant chain cancer vaccine | |
| CN115820696A (zh) | 治疗性多价HPV mRNA疫苗及其制备方法 | |
| Daemi et al. | Different domains of glycoprotein 96 influence HPV16 E7 DNA vaccine potency via electroporation mediated delivery in tumor mice model | |
| JP2009279006A (ja) | 抗原提示細胞におけるエピトープ同調 | |
| US20050100558A1 (en) | Heterologous boosting immunizations | |
| WO1997039771A1 (en) | Heterologous boosting immunizations | |
| Harui et al. | Vaccination with helper-dependent adenovirus enhances the generation of transgene-specific CTL | |
| CN110168086B (zh) | 疟疾疫苗 | |
| Adamina et al. | Advanced liposomal vectors as cancer vaccines in melanoma immunotherapy | |
| RU2808567C2 (ru) | Противораковая вакцина с инвариантной цепью из костистых рыб | |
| US8921534B2 (en) | Enhancement of the immune response using CD36-binding domain | |
| Wysocki et al. | The 14th European Immunology Meeting-EFIS 2000 | |
| CA2386415A1 (en) | New lymphocytes, a process for preparing the same and their use in therapeutics | |
| Chamberlain et al. | THE USE OF RECOMBINANT POXVIRUSES AS A PARADIGM FOR THE DEVELOPMENT OF ANTI-CANCER VACCINES | |
| HK1205182B (en) | Adenoviruses expressing heterologous tumor-associated antigens |